Rivastigmine in the Treatment of Postoperative Delirium: a Pilot Clinical Trial

• Status: Completed
• Trial end date: 2010-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether preoperative administration of Rivastigmine prevents the incidence of postoperative delirium in patients undergoing major surgery as well as postoperative cognitive dysfunction.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: New York University School of Medicine; NYU Langone Health
• Collaborator: Novartis
• Treatments: Rivastigmine

Criteria

Inclusion Criteria:

65 ≥ y.o. undergoing major elective surgery over 2 hours in length with one or more of the following:

• Preoperative cognitive impairment

• Age > 70 y.o.

• Use of psychoactive medications

• History of prior delirium

• Severe illness/co-morbidity

Exclusion Criteria:

• Delirium on admission Profound dementia No spoken/written English An emergent procedure Hypersensitivity to Rivastigmine